GWMIA
HZNP

Global Wealth Management Investment Advisory’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$7K – 686
2019
Q4 		$7K Buy
+200
New +$6.13K ﹤0.01% 411

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Global Wealth Management Investment Advisory's HZNP Position: Q1 2020 in Review

Global Wealth Management Investment Advisory sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2020, closing a stake of 200 shares — an estimated $7K sold.

Global Wealth Management Investment Advisory first reported a position in HZNP in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 295 funds tracked by Wall St. Rank hold HZNP as of Q1 2020.

  • Global Wealth Management Investment Advisory reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Global Wealth Management Investment Advisory sold 200 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2020, an estimated $7K.
  • Global Wealth Management Investment Advisory first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 1 quarter.
  • Global Wealth Management Investment Advisory's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7K in Q4 2019.
  • 295 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2020.

Based on Global Wealth Management Investment Advisory's 13F filing for Q1 2020, filed 14 May 2020.